Pulmatrix, Inc. reported a net loss of $5.2 million for the fiscal year ending December 31, 2025, a decrease from a loss of $9.6 million in the previous year. The company did not generate any revenue in 2025, a significant drop from $7.8 million in 2024, primarily due to the completion of the wind-down of the PUR1900 Phase 2b clinical trial. Operating expenses totaled $5.2 million, down from $17.6 million in 2024, reflecting reduced research and development costs following the termination of several clinical programs and a decrease in general and administrative expenses.
In a strategic move, Pulmatrix entered into a merger agreement with Cullgen Inc. on November 13, 2024, which was approved by its stockholders in June 2025. The merger is expected to enhance Pulmatrix's capabilities and market position, although it remains contingent on regulatory approvals, including from the China Securities Regulatory Commission (CSRC). As of the filing date, the company had not yet received this approval, and the merger's completion is uncertain. The company has also paused the development of its product candidates, including PUR3100, PUR1800, and PUR1900, while exploring monetization opportunities for these assets.
Pulmatrix's workforce has been significantly reduced, with only two full-time employees reported as of December 31, 2025. The company has shifted its focus to external resources for research and development, which may impact its operational capabilities. The filing indicates that the company anticipates continued operating losses and will require additional funding to support its operations and potential product development in the future.
Looking ahead, Pulmatrix's future operations are heavily dependent on the successful completion of the merger with Cullgen and the ability to secure additional funding. The company has expressed uncertainty regarding its ability to continue as a going concern if it cannot raise sufficient capital. The management has indicated that it will explore various avenues for funding, including equity offerings and strategic collaborations, to support its ongoing activities and potential product commercialization.
About Pulmatrix, Inc.
Pulmatrix, Inc. is a biopharmaceutical company specializing in inhaled therapies using its proprietary iSPERSE dry powder platform. It develops treatments for respiratory diseases and CNS disorders, including migraine, COPD, and ABPA. The company focuses on innovative drug delivery, aiming to improve efficacy and safety, and seeks strategic partnerships and monetization of its clinical assets in the global respiratory and neurological markets.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.